ChromoTek has launched next level of secondary antibodies
- Bild-Infos
- Download
Ein Dokument
The next level of secondary antibodies: Nanobodies for advanced detection
Martinsried, Germany, June 26, 2019 - ChromoTek GmbH is a pioneer in the development and marketing of alpaca Nanobodies, also called VHHs. In contrast to traditional antibodies, Nanobodies consist of one single polypeptide chain; they are 15 kDa and the smallest antibodies known.
ChromoTek has launched novel Nano-Secondaries for the detection of primary antibodies. These innovative secondary antibodies consist of Alexa Fluor® conjugated Nanobodies that bind to mouse subclass IgGs and rabbit IgG with high affinity & specificity.
Nano-Secondaries offer a plethora of advantages to researchers: They save time and manipulation by the simultaneous incubation of primary antibody and Nano-Secondary, also called one-step staining for both immunofluorescence and Western blotting. Furthermore, Nano-Secondaries are about 10 times smaller than conventional secondary antibodies. The small size enables better tissue penetration, antigen access, and decreases the distance between epitope and label. Hence, they are ideal probes for super-resolution microscopy. Also, ChromoTek selects only Nanobodies with the desired specificity during development; Nanobodies that cross-react to both IgGs from other commonly used species' IgGs and to other IgG subclasses are eliminated. Therefore, our Nano-Secondaries have an ultra-high specificity and hence do not require any kind of pre-adsorption. In addition, Nano-Secondaries are well suited for parallel detection of multiple primary antibodies, either from different species or even from different subclasses of the same species as shown for three mouse antibodies in figure. Finally, ChromoTek's Nano-Secondaries are recombinantly produced, virtually without lot-to-lot variation. The manufacturing process is totally animal free, though Nanobodies are generated from immunization of alpacas and llamas.
Of the Nano-Secondaries' launch, CEO Marion Jung said, "The new Nano-Secondaries are game changers for immunostaining. With higher resolution imaging, faster stainings for IF and Western blotting, multiplexing, and through characterization and documentation our Nano-Secondaries set a new level for secondary antibodies."
ChromoTek Nano-Secondaries are at the forefront of antibody validation: They fulfil recently discussed requirements on antibody quality. Our Nano-Secondaries are recombinantly manufactured, highly characterized and thoroughly validated - for the first time this concept has been applied to secondary antibodies. Furthermore, Nano-Secondaries bind in a site-specific manner and with a specific degree of labelling.
For more information see www.chromotek.com.
Figure Legend:
Multiplexed immunostaining of HeLa cells with three subclass-specific mouse primary and three alpaca anti-mouse Nano-Secondaries:
Grey: Mouse anti-Vimentin IgG1 primary antibody and alpaca anti-mouse IgG1 VHH Alexa Fluor 647.
Green: Mouse anti-Lamin A/C IgG2b primary antibody and alpaca anti-mouse IgG2b VHH Alexa Fluor 488.
Red: Mouse anti-MOT IgG3 primary antibody and alpaca anti-mouse IgG3 VHH Alexa Fluor 568. Scale bar, 10 µm.
Confocal images were acquired with a Leica TCS SP8 microscope, 100x oil objective, and deconvolved with Huygens Professional (SVI). Images were recorded at the Core Facility Bioimaging at the Biomedical Center, LMU Munich.
You can also download the image at https://www.chromotek.com/fileadmin/content/Images/Nano-Secondaries/Mouse_IgG1/ChromoTek_TripleMouse_Alltogether.png
Copyright images: © ChromoTek GmbH
About ChromoTek:
ChromoTek pioneered the development and commercialization of Nanobody-based research reagents. As a market and product leader for high quality and reliable Nanobody-based reagents, we assist scientists' research world-wide. In addition, ChromoTek is a trusted service provider of custom-made Nanobodies for the pharmaceutical industry. Founded in 2008 ChromoTek has offices in Martinsried, Germany, and Hauppauge, NY. More information at www.chromotek.com.
About the Innovation and Start-Up Center Biotechnology (IZB):
The company IZB mbH, founded in 1995, is the operating company of the Innovation and Start-Up Centers Biotechnology in Planegg-Martinsried and Freising-Weihenstephan, and has developed into one of the top ten renowned biotechnology centers in the world. More than 50 biotech companies with more than 600 employees are currently located on an area covering 26,000 m2. This is where work focuses on developing drugs against the most severe diseases such as cancer, Alzheimer's disease and various autoimmune diseases -and there are already many successes. At the IZB Freising-Weihenstephan - 15 minutes from the airport - scientists are working on developments in the field of life sciences. An essential criterion for the success of the IZBs is the proximity to top research on the Martinsried / Grosshadern Campus. The new infrastructure measures, such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Chemistry College Elhardt, the two kindergartens BioKids and BioKids2, as well as the two restaurants SEVEN AND MORE and Café Freshmaker, have become decisive location factors. Successful companies that have emerged from the IZB include, for example, Medigene AG, Morphosys AG, Micromet GmbH (now Amgen AG), Octopharma GmbH and Corimmun (today Janssen-Cilag). More information at www.izb-online.de.
Press contact ChromoTek GmbH:
Veronika Bösl
ChromoTek GmbH
Am Klopferspitz 19
82152 Planegg-Martinsried, Germany
Tel.: +49 (0)89 124 148 8-0
Mail: v.boesl@chromotek.com
Website: www.chromotek.com
Press contact IZB:
Susanne Simon
Head of Public Relations
Fördergesellschaft IZB mbH, Innovations- und Gründerzentrum Biotechnologie
Am Klopferspitz 19
82152 Planegg-Martinsried, Germany
Tel.: +49 (0)89 55 279 48-17
Mobil: +49 (0)172 86 66 093
E-Mail: presse@izb-online.de
Website: www.izb-online.de
Managing Director: Dr. Peter Hanns Zobel Munich Local Court HRB 111930 The information transmitted is intended only for the person to which it is addressed and may contain confidential and/or privileged material. Any retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by persons other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer. Thank you!